Ulcerative Colitis - Pipeline Review, H2 2011

Global Markets Direct, September 2011, Pages: 184

Ulcerative Colitis - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Ulcerative Colitis - Pipeline Review, H2 2011', provides an overview of the Ulcerative Colitis therapeutic pipeline. This report provides information on the therapeutic development for Ulcerative Colitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ulcerative Colitis. 'Ulcerative Colitis - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Ulcerative Colitis.
- A review of the Ulcerative Colitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Ulcerative Colitis pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Ulcerative Colitis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Ulcerative Colitis pipeline depth and focus of Ulcerative Colitis therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Ulcerative Colitis Overview
Therapeutics Development
An Overview of Pipeline Products for Ulcerative Colitis
Ulcerative Colitis Therapeutics under Development by Companies
Ulcerative Colitis Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Ulcerative Colitis Therapeutics - Products under Development by Companies
Ulcerative Colitis Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Ulcerative Colitis Therapeutics Development
Bristol-Myers Squibb Company
Johnson & Johnson
Smith & Nephew Plc
F. Hoffmann-La Roche Ltd.
Abbott Laboratories
Biogen Idec Inc.
Amgen Inc.
Athersys, Inc.
GlaxoSmithKline plc
Takeda Pharmaceutical Company Limited
Mochida Pharmaceutical Co., Ltd.
Histogen, Inc.
Novartis AG
Samyang Corporation
Astellas Pharma Inc.
Elan Corporation, plc
Pfizer Inc.
Salix Pharmaceuticals, Ltd.
Warner Chilcott Limited
Zeria Pharmaceutical Co Ltd
Genmab A/S
Shire Plc
Bayer AG
4SC AG
Alizyme plc
Hollis-Eden Pharmaceuticals, Inc.
Karo Bio
Callisto Pharmaceuticals, Inc.
Ore Pharmaceuticals Inc
Cosmo Pharmaceuticals S.p.A
Cerimon Pharmaceuticals, Inc.
Pluristem Therapeutics Inc.
AGI Therapeutics plc
Proximagen Neuroscience plc.
InDex Pharmaceuticals AB
ActogeniX NV
Am-Pharma B.V.
Palau Pharma S.A
7TM Pharma A/S
Asphelia Pharmaceuticals, Inc.
Inotek Pharmaceuticals Corporation
Txcell SA
Atlantic Pharmaceuticals, Inc.
KYORIN Pharmaceutical Co., Ltd.
S.L.A. Pharma AG
TikoMed AB
Dr. Falk Pharma GmbH
Centocor Ortho Biotech, Inc.
Transcription Factor Therapeutics, Inc.
Zeltia, S.A.
Kemin Industries, Inc.
Altheus Therapeutics, Inc.
LIPID THERAPEUTICS GmbH
Immune Technologies and Medicine
Sigmoid Pharma.
Ulcerative Colitis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Lialda - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RG7413 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ASP3291 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ELND004 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AEB071 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HMPL-004 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AG011 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TM30339 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Triolex - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Regenica - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Avonex - Drug Profile
ORE1001 - Drug Profile
AM3301 - Drug Profile
UC1-TX - Drug Profile
OvaSave - Drug Profile
AGI-022 - Drug Profile
MD-0901 - Drug Profile
Remicade - Drug Profile
IMA-638 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LT-02 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KRP-203 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Z-206 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IMS - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PUR0110 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ASP-2002 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Avonex - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Avrina - Drug Profile
Product Description
Mechanism of Action
R&D Progress
5-ASA - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Simponi - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Nicotine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AMG 181 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CyCol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Avandia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cimzia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Simulect - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ALTH12 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cannabis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SP-333 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PLX–IBD - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TM-110 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ulcerative Colitis Therapeutics – Drug Profile Updates
Ulcerative Colitis Therapeutics - Discontinued Products
Ulcerative Colitis - Featured News
Sep 20, 2011: Santarus Announces Supportive Top-Line Results From Budesonide MMX Extended Use Study
Sep 01, 2011: Johnson & Johnson Receives Health Canada Approval For Remicade In Treatment Of Pediatric Ulcerative Colitis
Jul 21, 2011: FDA Advisory Committee Recommends Approval Of REMICADE For Treatment Of Pediatric Ulcerative Colitis
Jul 18, 2011: Shire Announces Lialda Approval In US For Maintenance Of Remission Of Ulcerative Colitis
Jun 22, 2011: Lipid Therapeutics Announces Positive Topline Phase IIb Results Of LT-02 In Patients With Ulcerative Colitis
Jun 07, 2011: Health Canada Grants MEZAVANT New Expanded Indication For Maintenance Of Remission Of Ulcerative Colitis
May 10, 2011: Abbott's HUMIRA Meets Primary Endpoints In Phase III Ulcerative Colitis Study
May 09, 2011: Johnson & Johnson Reports Promising Phase III Study Results Of REMICADE In Moderate To Severe Ulcerative Colitis
Apr 15, 2011: Merck and Johnson & Johnson Reach Agreement on Distribution Rights for Remicade and Simponi
Apr 15, 2011: Merck and Johnson & Johnson Reach Agreement on Distribution Rights for Remicade and Simponi
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Ulcerative Colitis, H2 2011
Products under Development for Ulcerative Colitis – Comparative Analysis, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Comparative Analysis by Late Stage Development, H2 2011
Comparative Analysis by Mid Clinical Stage Development, H2 2011
Comparative Analysis by Early Clinical Stage Development, H2 2011
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Bristol-Myers Squibb Company, H2 2011
Johnson & Johnson, H2 2011
Smith & Nephew Plc, H2 2011
F. Hoffmann-La Roche Ltd., H2 2011
Abbott Laboratories, H2 2011
Biogen Idec Inc., H2 2011
Amgen Inc., H2 2011
Athersys, Inc., H2 2011
GlaxoSmithKline plc, H2 2011
Takeda Pharmaceutical Company Limited, H2 2011
Mochida Pharmaceutical Co., Ltd., H2 2011
Histogen, Inc., H2 2011
Novartis AG, H2 2011
Samyang Corporation, H2 2011
Astellas Pharma Inc., H2 2011
Elan Corporation, plc, H2 2011
Pfizer Inc., H2 2011
Salix Pharmaceuticals, Ltd., H2 2011
Warner Chilcott Limited, H2 2011
Zeria Pharmaceutical Co Ltd, H2 2011
Genmab A/S, H2 2011
Shire Plc, H2 2011
Bayer AG, H2 2011
4SC AG, H2 2011
Alizyme plc, H2 2011
Hollis-Eden Pharmaceuticals, Inc., H2 2011
Karo Bio, H2 2011
Callisto Pharmaceuticals, Inc., H2 2011
Ore Pharmaceuticals Inc, H2 2011
Cosmo Pharmaceuticals S.p.A, H2 2011
Cerimon Pharmaceuticals, Inc., H2 2011
Pluristem Therapeutics Inc., H2 2011
AGI Therapeutics plc, H2 2011
Proximagen Neuroscience plc., H2 2011
InDex Pharmaceuticals AB, H2 2011
ActogeniX NV, H2 2011
Am-Pharma B.V., H2 2011
Palau Pharma S.A, H2 2011
7TM Pharma A/S, H2 2011
Asphelia Pharmaceuticals, Inc., H2 2011
Inotek Pharmaceuticals Corporation, H2 2011
Txcell SA, H2 2011
Atlantic Pharmaceuticals, Inc., H2 2011
KYORIN Pharmaceutical Co., Ltd., H2 2011
S.L.A. Pharma AG, H2 2011
TikoMed AB, H2 2011
Dr. Falk Pharma GmbH, H2 2011
Centocor Ortho Biotech, Inc., H2 2011
Transcription Factor Therapeutics, Inc., H2 2011
Zeltia, S.A., H2 2011
Kemin Industries, Inc., H2 2011
Altheus Therapeutics, Inc., H2 2011
LIPID THERAPEUTICS GmbH, H2 2011
Immune Technologies and Medicine, H2 2011
Sigmoid Pharma., H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Ulcerative Colitis Therapeutics – Drug Profile Updates
Discontinued Products

List of Figures
Number of Products under Development for Ulcerative Colitis, H2 2011
Products under Development for Ulcerative Colitis – Comparative Analysis, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Late Stage Products, H2 2011
Mid Clinical Stage Products, H2 2011
Early Clinical Stage Products, H2 2011
Discovery and Pre-Clinical Stage Products, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products, H2 2011
Assessment by Route of Administration, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Assessment by Stage and Molecule Type, H2 2011

Customers who bought this item also bought

• Ulcerative Colitis (Event Driven)
• Global Ulcerative Colitis Drug Pipeline Capsule - 2012
• Gastrointestinal Disorder Therapeutics to 2016 - High Unmet Needs Triggering Strong Growth in Crohn's Disease and Irritable Bowel Syndrome Markets
• Bone Marrow Transplantation – Pipeline Review, H1 2013
• Pipeline Insight: Inflammatory Bowel Disease - Varied drug targets to broaden future therapy options
• Ulcerative Colitis: KOL Insights on Treatment Practices and Unmet Needs
• Brain Tumor – Pipeline Review, H1 2013
• Smoking Cessation – Pipeline Review, H1 2013
• Substance (Drug) Abuse – Pipeline Review, H1 2013
• Liver Transplantation – Pipeline Review, H1 2013